RSV Vaccines Demonstrate Sustained Effectiveness for Older Adults

The 2 RSV vaccines approved in 2023 for adults aged 60 years or older (Arexvy, GSK and Abrysvo, Pfizer) have demonstrated¹ effectiveness in preventing related hospitalizations over 2 seasons, although with some waning in the second year after…